Novo Nordisk's anti-inflammatory drug ziltivekimab fails to cut major heart events in Phase 3 trial
Novo Nordisk reported that its investigational anti‑inflammatory antibody, ziltivekimab, did not reduce the incidence of major cardiovascular events in a pivotal Phase 3 study.
The trial enrolled more than 6,300 participants who had existing heart disease, kidney disease and elevated inflammation. While the drug lowered laboratory markers of inflammation, it did not translate into fewer heart attacks, strokes or cardiovascular‑related deaths.
The news sent Novo Nordisk shares down about 7% on the day of the announcement and raised doubts about the broader strategy of targeting inflammation to prevent cardiovascular complications.
This writeup was produced by pharmadog from original reporting by STAT.
Original headline: “STAT+: Novo Nordisk inflammation-targeting drug misses mark in heart disease study”
read at STAT ↗
comments(0)
5-min edit window · permanent after that